Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotin...

Descripción completa

Detalles Bibliográficos
Autores principales: Passaro, Antonio, Lazzari, Chiara, Karachaliou, Niki, Spitaleri, Gianluca, Pochesci, Alessia, Catania, Chiara, Rosell, Rafael, de Marinis, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074703/
https://www.ncbi.nlm.nih.gov/pubmed/27799783
http://dx.doi.org/10.2147/OTT.S98347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074703/
https://www.ncbi.nlm.nih.gov/pubmed/27799783
http://dx.doi.org/10.2147/OTT.S98347

Ejemplares similares